Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 88

1.

Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.

Coit DG, Thompson JA, Albertini MR, Barker C, Carson WE, Contreras C, Daniels GA, DiMaio D, Fields RC, Fleming MD, Freeman M, Galan A, Gastman B, Guild V, Johnson D, Joseph RW, Lange JR, Nath S, Olszanski AJ, Ott P, Gupta AP, Ross MI, Salama AK, Skitzki J, Sosman J, Swetter SM, Tanabe KK, Wuthrick E, McMillian NR, Engh AM.

J Natl Compr Canc Netw. 2019 Apr 1;17(4):367-402. doi: 10.6004/jnccn.2019.0018.

PMID:
30959471
2.

Drug-associated vasculitis occurring after treatment with pembrolizumab.

Tolaymat OA, Pinkston O, Wang B, Schenk WB, Joseph RW, Mergo PJ, Berianu F.

Rheumatology (Oxford). 2019 Aug 1;58(8):1501-1503. doi: 10.1093/rheumatology/kez051. No abstract available.

PMID:
30892627
3.

Desmoplastic melanoma: a brief review and the efficacy of immunotherapy.

Ochoa CE, Joseph RW.

Expert Rev Anticancer Ther. 2019 Mar;19(3):205-207. doi: 10.1080/14737140.2019.1574573. Epub 2019 Feb 4. No abstract available.

PMID:
30686076
4.

Inositol hexaphosphate plus inositol induced complete remission in stage IV melanoma: a case report.

Khurana S, Baldeo C, Joseph RW.

Melanoma Res. 2019 Jun;29(3):322-324. doi: 10.1097/CMR.0000000000000577.

PMID:
30615010
5.

Correction: Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab.

Joseph RW, Elassaiss-Schaap J, Kefford R, Hwu WJ, Wolchok JD, Joshua AM, Ribas A, Hodi FS, Hamid O, Robert C, Daud A, Dronca R, Hersey P, Weber JS, Patnaik A, de Alwis DP, Perrone A, Zhang J, Kang SP, Ebbinghaus S, Anderson KM, Gangadhar TC.

Clin Cancer Res. 2018 Dec 1;24(23):6098. doi: 10.1158/1078-0432.CCR-18-3340. No abstract available.

PMID:
30510087
6.

Factors associated with immunotherapy selection in patients with advanced melanoma.

Joseph RW, Shillington AC, Macahilig C, Diede SJ, Dave V, Harshaw Q, Liu FX.

Immunotherapy. 2018 Nov;10(16):1361-1369. doi: 10.2217/imt-2018-0150. Epub 2018 Nov 8.

7.

Adjuvant Antiangiogenic Agents in Post-nephrectomy Renal Cell Carcinoma: A Systematic Review and Meta-analysis.

Sonbol MB, Firwana B, Hilal T, Wang Z, Almader-Douglas D, Joseph RW, Ho TH.

Eur Urol Oncol. 2018 Jun;1(2):101-108. doi: 10.1016/j.euo.2018.03.012. Epub 2018 Mar 15.

8.

Publisher Correction: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma.

McDermott DF, Huseni MA, Atkins MB, Motzer RJ, Rini BI, Escudier B, Fong L, Joseph RW, Pal SK, Reeves JA, Sznol M, Hainsworth J, Rathmell WK, Stadler WM, Hutson T, Gore ME, Ravaud A, Bracarda S, Suárez C, Danielli R, Gruenwald V, Choueiri TK, Nickles D, Jhunjhunwala S, Piault-Louis E, Thobhani A, Qiu J, Chen DS, Hegde PS, Schiff C, Fine GD, Powles T.

Nat Med. 2018 Dec;24(12):1941. doi: 10.1038/s41591-018-0235-z.

PMID:
30291359
9.

Utility of ipilimumab in melanoma patients who progress on anti-PD-1 therapy.

Ochoa CE, Joseph RW.

Melanoma Manag. 2017 Sep;4(3):143-145. doi: 10.2217/mmt-2017-0010. Epub 2017 Jul 26. No abstract available.

10.

Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti-PD-1 Therapies in Metastatic Melanoma.

Johnson DB, Bordeaux J, Kim JY, Vaupel C, Rimm DL, Ho TH, Joseph RW, Daud AI, Conry RM, Gaughan EM, Hernandez-Aya LF, Dimou A, Funchain P, Smithy J, Witte JS, McKee SB, Ko J, Wrangle JM, Dabbas B, Tangri S, Lameh J, Hall J, Markowitz J, Balko JM, Dakappagari N.

Clin Cancer Res. 2018 Nov 1;24(21):5250-5260. doi: 10.1158/1078-0432.CCR-18-0309. Epub 2018 Jul 18.

11.

Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma.

McDermott DF, Huseni MA, Atkins MB, Motzer RJ, Rini BI, Escudier B, Fong L, Joseph RW, Pal SK, Reeves JA, Sznol M, Hainsworth J, Rathmell WK, Stadler WM, Hutson T, Gore ME, Ravaud A, Bracarda S, Suárez C, Danielli R, Gruenwald V, Choueiri TK, Nickles D, Jhunjhunwala S, Piault-Louis E, Thobhani A, Qiu J, Chen DS, Hegde PS, Schiff C, Fine GD, Powles T.

Nat Med. 2018 Jun;24(6):749-757. doi: 10.1038/s41591-018-0053-3. Epub 2018 Jun 4. Erratum in: Nat Med. 2018 Dec;24(12):1941.

12.

Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab.

Joseph RW, Elassaiss-Schaap J, Kefford R, Hwu WJ, Wolchok JD, Joshua AM, Ribas A, Hodi FS, Hamid O, Robert C, Daud A, Dronca R, Hersey P, Weber JS, Patnaik A, de Alwis DP, Perrone A, Zhang J, Kang SP, Ebbinghaus S, Anderson KM, Gangadhar TC.

Clin Cancer Res. 2018 Oct 15;24(20):4960-4967. doi: 10.1158/1078-0432.CCR-17-2386. Epub 2018 Apr 23. Erratum in: Clin Cancer Res. 2018 Dec 1;24(23):6098.

13.

Association Between Programmed Death-Ligand 1 Expression and the Vascular Endothelial Growth Factor Pathway in Angiosarcoma.

Bagaria SP, Gatalica Z, Maney T, Serie D, Parasramka M, Attia S, Krishna M, Joseph RW.

Front Oncol. 2018 Mar 22;8:71. doi: 10.3389/fonc.2018.00071. eCollection 2018.

14.

New-onset insulin-dependent diabetes due to nivolumab.

Zaied AA, Akturk HK, Joseph RW, Lee AS.

Endocrinol Diabetes Metab Case Rep. 2018 Mar 28;2018. pii: 17-0174. doi: 10.1530/EDM-17-0174. eCollection 2018.

15.

Sentinel lymph node biopsy in Merkel cell carcinoma: The Mayo Clinic experience of 150 patients.

Sims JR, Grotz TE, Pockaj BA, Joseph RW, Foote RL, Otley CC, Weaver AL, Jakub JW, Price DL.

Surg Oncol. 2018 Mar;27(1):11-17. doi: 10.1016/j.suronc.2017.10.005. Epub 2017 Oct 26.

PMID:
29549898
16.

Nivolumab in Renal Cell Carcinoma: Current Trends and Future Perspectives.

Ochoa CE, Joseph RW.

J Kidney Cancer VHL. 2018 Feb 6;5(1):15-18. doi: 10.15586/jkcvhl.2018.102. eCollection 2018. Review.

17.

High response rate to PD-1 blockade in desmoplastic melanomas.

Eroglu Z, Zaretsky JM, Hu-Lieskovan S, Kim DW, Algazi A, Johnson DB, Liniker E, Ben Kong, Munhoz R, Rapisuwon S, Gherardini PF, Chmielowski B, Wang X, Shintaku IP, Wei C, Sosman JA, Joseph RW, Postow MA, Carlino MS, Hwu WJ, Scolyer RA, Messina J, Cochran AJ, Long GV, Ribas A.

Nature. 2018 Jan 18;553(7688):347-350. doi: 10.1038/nature25187. Epub 2018 Jan 10.

18.

Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma.

Robert C, Ribas A, Hamid O, Daud A, Wolchok JD, Joshua AM, Hwu WJ, Weber JS, Gangadhar TC, Joseph RW, Dronca R, Patnaik A, Zarour H, Kefford R, Hersey P, Zhang J, Anderson J, Diede SJ, Ebbinghaus S, Hodi FS.

J Clin Oncol. 2018 Jun 10;36(17):1668-1674. doi: 10.1200/JCO.2017.75.6270. Epub 2017 Dec 28.

PMID:
29283791
19.

Patient and Oncology Nurse Preferences for the Treatment Options in Advanced Melanoma: A Discrete Choice Experiment.

Liu FX, Witt EA, Ebbinghaus S, DiBonaventura Beyer G, Basurto E, Joseph RW.

Cancer Nurs. 2019 Jan/Feb;42(1):E52-E59. doi: 10.1097/NCC.0000000000000557.

20.

NCCTG N0879 (Alliance): A randomized phase 2 cooperative group trial of carboplatin, paclitaxel, and bevacizumab ± everolimus for metastatic melanoma.

McWilliams RR, Allred JB, Slostad JA, Katipamula R, Dronca RS, Rumilla KM, Erickson LA, Bryce AH, Joseph RW, Kottschade LA, King DM, Leitch JM, Markovic SN.

Cancer. 2018 Feb 1;124(3):537-545. doi: 10.1002/cncr.31072. Epub 2017 Oct 17.

21.

Multicenter Validation of Enhancer of Zeste Homolog 2 Expression as an Independent Prognostic Marker in Localized Clear Cell Renal Cell Carcinoma.

Ho TH, Kapur P, Eckel-Passow JE, Christie A, Joseph RW, Serie DJ, Cheville JC, Thompson RH, Homayoun F, Panwar V, Brugarolas J, Parker AS.

J Clin Oncol. 2017 Nov 10;35(32):3706-3713. doi: 10.1200/JCO.2017.73.3238. Epub 2017 Oct 4.

22.

Comprehensive Genomic Profiling of a Rare Thyroid Follicular Dendritic Cell Sarcoma.

Davila JI, Starr JS, Attia S, Wang C, Knudson RA, Necela BM, Sarangi V, Sun Z, Ren Y, Casler JD, Menke DM, Oliver GR, Joseph RW, Copland JA, Parker AS, Kocher JA, Thompson EA, Smallridge RC, Asmann YW.

Rare Tumors. 2017 Sep 15;9(2):6834. doi: 10.4081/rt.2017.6834. eCollection 2017 Jul 3.

23.

Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study.

Necchi A, Joseph RW, Loriot Y, Hoffman-Censits J, Perez-Gracia JL, Petrylak DP, Derleth CL, Tayama D, Zhu Q, Ding B, Kaiser C, Rosenberg JE.

Ann Oncol. 2017 Dec 1;28(12):3044-3050. doi: 10.1093/annonc/mdx518.

24.

Patient and oncologist preferences for attributes of treatments in advanced melanoma: a discrete choice experiment.

Liu FX, Witt EA, Ebbinghaus S, DiBonaventura Beyer G, Shinde R, Basurto E, Joseph RW.

Patient Prefer Adherence. 2017 Aug 14;11:1389-1399. doi: 10.2147/PPA.S140226. eCollection 2017.

25.

Correlation Between Molecular Subclassifications of Clear Cell Renal Cell Carcinoma and Targeted Therapy Response.

Ho TH, Choueiri TK, Wang K, Karam JA, Chalmers Z, Frampton G, Elvin JA, Johnson A, Liu X, Lin Y, Joseph RW, Stanton ML, Miller VA, Stephens PJ, Ross JS, Ali SM, Pal SK.

Eur Urol Focus. 2016 Jun;2(2):204-209. doi: 10.1016/j.euf.2015.11.007. Epub 2015 Dec 9.

PMID:
28723536
26.

Validation of Gene Expression Signatures to Identify Low-risk Clear-cell Renal Cell Carcinoma Patients at Higher Risk for Disease-related Death.

Parasramka M, Serie DJ, Asmann YW, Eckel-Passow JE, Castle EP, Stanton ML, Leibovich BC, Thompson RH, Thompson EA, Parker AS, Ho TH, Joseph RW.

Eur Urol Focus. 2016 Dec 15;2(6):608-615. doi: 10.1016/j.euf.2016.03.008. Epub 2016 Apr 2.

PMID:
28723492
27.

The Feasibility and Safety of Surgery in Patients Receiving Immune Checkpoint Inhibitors: A Retrospective Study.

Elias AW, Kasi PM, Stauffer JA, Thiel DD, Colibaseanu DT, Mody K, Joseph RW, Bagaria SP.

Front Oncol. 2017 Jun 12;7:121. doi: 10.3389/fonc.2017.00121. eCollection 2017.

28.

Non-clear cell renal cell carcinomas: biological insights and therapeutic challenges and opportunities.

Malouf GG, Joseph RW, Shah AY, Tannir NM.

Clin Adv Hematol Oncol. 2017 May;15(5):409-418. Review.

PMID:
28591094
29.

Clinical Features of Acquired Resistance to Anti-PD-1 Therapy in Advanced Melanoma.

Wang DY, Eroglu Z, Ozgun A, Leger PD, Zhao S, Ye F, Luke JJ, Joseph RW, Haq R, Ott PA, Hodi FS, Sosman JA, Johnson DB, Buchbinder EI.

Cancer Immunol Res. 2017 May;5(5):357-362. doi: 10.1158/2326-6066.CIR-16-0287. Epub 2017 Apr 10.

30.

BAP1 and PBRM1 in metastatic clear cell renal cell carcinoma: tumor heterogeneity and concordance with paired primary tumor.

Eckel-Passow JE, Serie DJ, Cheville JC, Ho TH, Kapur P, Brugarolas J, Thompson RH, Leibovich BC, Kwon ED, Joseph RW, Parker AS.

BMC Urol. 2017 Mar 21;17(1):19. doi: 10.1186/s12894-017-0209-3.

31.

Nivolumab treatment for advanced renal cell carcinoma: Considerations for clinical practice.

Joseph RW, Chatta G, Vaishampayan U.

Urol Oncol. 2017 Apr;35(4):142-148. doi: 10.1016/j.urolonc.2017.01.017. Epub 2017 Mar 2. Review.

PMID:
28259541
32.

Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma.

Zimmer L, Apuri S, Eroglu Z, Kottschade LA, Forschner A, Gutzmer R, Schlaak M, Heinzerling L, Krackhardt AM, Loquai C, Markovic SN, Joseph RW, Markey K, Utikal JS, Weishaupt C, Goldinger SM, Sondak VK, Zager JS, Schadendorf D, Khushalani NI.

Eur J Cancer. 2017 Apr;75:47-55. doi: 10.1016/j.ejca.2017.01.009. Epub 2017 Feb 17.

PMID:
28214657
33.

Molecular Modeling and Functional Analysis of Exome Sequencing-Derived Variants of Unknown Significance Identify a Novel, Constitutively Active FGFR2 Mutant in Cholangiocarcinoma.

Egan JB, Marks DL, Hogenson TL, Vrabel AM, Sigafoos AN, Tolosa EJ, Carr RM, Safgren SL, Hesles EE, Almada LL, Romecin-Duran PA, Iguchi E, Ala'Aldeen A, Kocher JA, Oliver GR, Prodduturi N, Mead DW, Hossain A, Huneke NE, Tagtow CM, Ailawadhi S, Ansell SM, Banck MS, Bryce AH, Carballido EM, Chanan-Khan AA, Curtis KK, Resnik E, Gawryletz CD, Go RS, Halfdanarson TR, Ho TH, Joseph RW, Kapoor P, Mansfield AS, Meurice N, Nageswara Rao AA, Nowakowski GS, Pardanani A, Parikh SA, Cheville JC, Feldman AL, Ramanathan RK, Robinson SI, Tibes R, Finnes HD, McCormick JB, McWilliams RR, Jatoi A, Patnaik MM, Silva AC, Wieben ED, McAllister TM, Rumilla KM, Kerr SE, Lazaridis KN, Farrugia G, Stewart AK, Clark KJ, Kennedy EJ, Klee EW, Borad MJ, Fernandez-Zapico ME.

JCO Precis Oncol. 2017;2017. doi: 10.1200/PO.17.00018. Epub 2017 Aug 1.

34.

Differential gene expression profiling of matched primary renal cell carcinoma and metastases reveals upregulation of extracellular matrix genes.

Ho TH, Serie DJ, Parasramka M, Cheville JC, Bot BM, Tan W, Wang L, Joseph RW, Hilton T, Leibovich BC, Parker AS, Eckel-Passow JE.

Ann Oncol. 2017 Mar 1;28(3):604-610. doi: 10.1093/annonc/mdw652.

35.

Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.

Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, Loriot Y, Necchi A, Hoffman-Censits J, Perez-Gracia JL, Dawson NA, van der Heijden MS, Dreicer R, Srinivas S, Retz MM, Joseph RW, Drakaki A, Vaishampayan UN, Sridhar SS, Quinn DI, Durán I, Shaffer DR, Eigl BJ, Grivas PD, Yu EY, Li S, Kadel EE 3rd, Boyd Z, Bourgon R, Hegde PS, Mariathasan S, Thåström A, Abidoye OO, Fine GD, Bajorin DF; IMvigor210 Study Group.

Lancet. 2017 Jan 7;389(10064):67-76. doi: 10.1016/S0140-6736(16)32455-2. Epub 2016 Dec 8. Erratum in: Lancet. 2017 Aug 26;390(10097):848.

36.

Clear Cell Type A and B Molecular Subtypes in Metastatic Clear Cell Renal Cell Carcinoma: Tumor Heterogeneity and Aggressiveness.

Serie DJ, Joseph RW, Cheville JC, Ho TH, Parasramka M, Hilton T, Thompson RH, Leibovich BC, Parker AS, Eckel-Passow JE.

Eur Urol. 2017 Jun;71(6):979-985. doi: 10.1016/j.eururo.2016.11.018. Epub 2016 Nov 26.

37.

Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma.

Rini BI, McDermott DF, Hammers H, Bro W, Bukowski RM, Faba B, Faba J, Figlin RA, Hutson T, Jonasch E, Joseph RW, Leibovich BC, Olencki T, Pantuck AJ, Quinn DI, Seery V, Voss MH, Wood CG, Wood LS, Atkins MB.

J Immunother Cancer. 2016 Nov 15;4:81. eCollection 2016.

38.

A Study of Combination Bicalutamide and Raloxifene for Patients With Castration-Resistant Prostate Cancer.

Ho TH, Nunez-Nateras R, Hou YX, Bryce AH, Northfelt DW, Dueck AC, Wong B, Stanton ML, Joseph RW, Castle EP.

Clin Genitourin Cancer. 2017 Apr;15(2):196-202.e1. doi: 10.1016/j.clgc.2016.08.026. Epub 2016 Sep 8.

PMID:
27771244
39.

NCCN Guidelines Insights: Melanoma, Version 3.2016.

Coit DG, Thompson JA, Algazi A, Andtbacka R, Bichakjian CK, Carson WE 3rd, Daniels GA, DiMaio D, Fields RC, Fleming MD, Gastman B, Gonzalez R, Guild V, Johnson D, Joseph RW, Lange JR, Martini MC, Materin MA, Olszanski AJ, Ott P, Gupta AP, Ross MI, Salama AK, Skitzki J, Swetter SM, Tanabe KK, Torres-Roca JF, Trisal V, Urist MM, McMillian N, Engh A.

J Natl Compr Canc Netw. 2016 Aug;14(8):945-58.

PMID:
27496110
40.

Patient-derived tumor xenograft models for melanoma drug discovery.

Harris AL, Joseph RW, Copland JA.

Expert Opin Drug Discov. 2016 Sep;11(9):895-906. doi: 10.1080/17460441.2016.1216968. Review.

PMID:
27454070
41.

Efficacy of immunotherapy for metastatic mucosal melanoma.

Shreders A, Joseph RW.

Immunotherapy. 2016 Jul;8(8):843-5. doi: 10.2217/imt-2016-0036. Review. No abstract available.

PMID:
27381682
42.

Detection of tumor-associated cells in cryopreserved peripheral blood mononuclear cell samples for retrospective analysis.

Zhu P, Stanton ML, Castle EP, Joseph RW, Adams DL, Li S, Amstutz P, Tang CM, Ho TH.

J Transl Med. 2016 Jul 2;14(1):198. doi: 10.1186/s12967-016-0953-2.

43.

Treatment of in-transit and metastatic melanoma in two patients treated with ipilimumab and topical imiquimod.

Joseph RW, Cappel M, Tzou K, Bagaria S, Gilstrap C, Swaika A, Jambusaria-Pahlajani A.

Melanoma Res. 2016 Aug;26(4):409-12. doi: 10.1097/CMR.0000000000000247.

PMID:
27138458
44.

Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma.

Ribas A, Hamid O, Daud A, Hodi FS, Wolchok JD, Kefford R, Joshua AM, Patnaik A, Hwu WJ, Weber JS, Gangadhar TC, Hersey P, Dronca R, Joseph RW, Zarour H, Chmielowski B, Lawrence DP, Algazi A, Rizvi NA, Hoffner B, Mateus C, Gergich K, Lindia JA, Giannotti M, Li XN, Ebbinghaus S, Kang SP, Robert C.

JAMA. 2016 Apr 19;315(15):1600-9. doi: 10.1001/jama.2016.4059. Erratum in: JAMA. 2016 Jun 14;315(22):2472.

PMID:
27092830
45.

Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology.

Coit DG, Thompson JA, Algazi A, Andtbacka R, Bichakjian CK, Carson WE 3rd, Daniels GA, DiMaio D, Ernstoff M, Fields RC, Fleming MD, Gonzalez R, Guild V, Halpern AC, Hodi FS Jr, Joseph RW, Lange JR, Martini MC, Materin MA, Olszanski AJ, Ross MI, Salama AK, Skitzki J, Sosman J, Swetter SM, Tanabe KK, Torres-Roca JF, Trisal V, Urist MM, McMillian N, Engh A.

J Natl Compr Canc Netw. 2016 Apr;14(4):450-73.

PMID:
27059193
46.

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.

Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, Dawson N, O'Donnell PH, Balmanoukian A, Loriot Y, Srinivas S, Retz MM, Grivas P, Joseph RW, Galsky MD, Fleming MT, Petrylak DP, Perez-Gracia JL, Burris HA, Castellano D, Canil C, Bellmunt J, Bajorin D, Nickles D, Bourgon R, Frampton GM, Cui N, Mariathasan S, Abidoye O, Fine GD, Dreicer R.

Lancet. 2016 May 7;387(10031):1909-20. doi: 10.1016/S0140-6736(16)00561-4. Epub 2016 Mar 4.

47.

Loss of histone H3 lysine 36 trimethylation is associated with an increased risk of renal cell carcinoma-specific death.

Ho TH, Kapur P, Joseph RW, Serie DJ, Eckel-Passow JE, Tong P, Wang J, Castle EP, Stanton ML, Cheville JC, Jonasch E, Brugarolas J, Parker AS.

Mod Pathol. 2016 Jan;29(1):34-42. doi: 10.1038/modpathol.2015.123. Epub 2015 Oct 30.

48.

PD-1 and PD-L1 Expression in Renal Cell Carcinoma with Sarcomatoid Differentiation.

Joseph RW, Millis SZ, Carballido EM, Bryant D, Gatalica Z, Reddy S, Bryce AH, Vogelzang NJ, Stanton ML, Castle EP, Ho TH.

Cancer Immunol Res. 2015 Dec;3(12):1303-7. doi: 10.1158/2326-6066.CIR-15-0150. Epub 2015 Aug 25.

49.

Clear Cell Renal Cell Carcinoma Subtypes Identified by BAP1 and PBRM1 Expression.

Joseph RW, Kapur P, Serie DJ, Parasramka M, Ho TH, Cheville JC, Frenkel E, Parker AS, Brugarolas J.

J Urol. 2016 Jan;195(1):180-7. doi: 10.1016/j.juro.2015.07.113. Epub 2015 Aug 20.

50.

A Multidisciplinary Biospecimen Bank of Renal Cell Carcinomas Compatible with Discovery Platforms at Mayo Clinic, Scottsdale, Arizona.

Ho TH, Nateras RN, Yan H, Park JG, Jensen S, Borges C, Lee JH, Champion MD, Tibes R, Bryce AH, Carballido EM, Todd MA, Joseph RW, Wong WW, Parker AS, Stanton ML, Castle EP.

PLoS One. 2015 Jul 16;10(7):e0132831. doi: 10.1371/journal.pone.0132831. eCollection 2015.

Supplemental Content

Loading ...
Support Center